URGN logo

UroGen Pharma (URGN) EBITDA

Annual EBITDA

-$81.90 M
+$15.87 M+16.23%

December 31, 2023

Summary

Performance

1-Year Change

+16.23%

3-Year Change

+34.32%

5-Year Change

-6.7%

15-Year Change

-314.85%

URGN EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

21.46%
URGN annual EBITDA is higher than 21.46% of companies in Healthcare sector

High & Low

All-time High

$1.01 M
URGN annual EBITDA is currently -8201.29% below its historical high of $1.01 million

3-Year Low

-$107.60 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
URGN previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 14, 2025
URGN next annual earnings announcement is scheduled for Mar 14, 2025

OtherURGNprofitabilitymetrics:

Annual Revenue

$82.71 M
URGN annual revenue is $82.71 million

Annual Net Income

-$102.24 M
URGN annual net profit is -$102.24 million

Annual EBIT

-$83.61 M
URGN annual earnings before interest & taxes is -$83.61 million

Annual EPS

-$3.55
URGN annual earnings per share is -$3.55

Quarterly EBITDA

-$20.59 M
+$9.05 M+30.52%

September 30, 2024

Summary

Performance

3-Month Change

+30.52%

1-Year Change

-16.63%

3-Year Change

+30.79%

5-Year Change

+11.01%

URGN Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

21.99%
URGN quarterly EBITDA is higher than 21.99% of companies in Healthcare sector

High & Low

All-time High

$13.98 M
URGN quarterly EBITDA is currently -247.30% below its historical high of $13.98 million

3-Year Low

-$29.64 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
URGN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
URGN next earnings announcement is scheduled for Mar 14, 2025

OtherURGNprofitabilitymetrics:

Quarterly Revenue

$25.20 M
URGN quarterly revenue is $25.20 million

Quarterly Net Income

-$23.67 M
URGN quarterly net profit is -$23.67 million

Quarterly EBIT

-$20.86 M
URGN quarterly earnings before interest & taxes is -$20.86 million

Quarterly EPS

-$0.55
URGN quarterly earnings per share is -$0.55

TTM EBITDA

-$97.82 M
-$2.94 M-3.10%

September 30, 2024

Summary

Performance

3-Month Change

-3.1%

1-Year Change

-10.84%

3-Year Change

+9.05%

5-Year Change

+9.55%

URGN TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

18.5%
URGN TTM EBITDA is higher than 18.5% of companies in Healthcare sector

High & Low

All-time High

$4.57 M
URGN TTM EBITDA is currently -2239.59% below its historical high of $4.57 million

3-Year Low

-$109.42 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
URGN previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
URGN next earnings announcement is scheduled for Mar 14, 2025

OtherURGNprofitabilitymetrics:

TTM Revenue

$89.36 M
URGN TTM revenue is $89.36 million

TTM Net Income

-$115.38 M
URGN TTM net profit is -$115.38 million

TTM EBIT

-$99.13 M
URGN TTM earnings before interest & taxes is -$99.13 million

TTM EPS

-$3.09
URGN TTM earnings per share is -$3.09

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$81.90 M
URGN annual EBITDA is -$81.90 million

Annual Net Income

-$102.24 M
URGN annual net profit is -$102.24 million

Annual Interest Expense

$14.71 M
URGN annual interest expense is $14.71 million

Annual Income Tax

$3.92 M
URGN annual income tax is $3.92 million

Annual D&A

$1.71 M
URGN annual depreciation & amortization is $1.71 million

URGN EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+16.2%-16.6%-10.8%
3 y3 years+34.3%+30.8%+9.1%
5 y5 years-6.7%+11.0%+9.6%

URGN EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+23.9%-16.6%+30.5%-19.4%+10.6%
5 y5-yearat high+34.3%-16.6%+47.8%-19.4%+28.9%
alltimeall time-8201.3%+34.3%-247.3%+47.8%-2239.6%+28.9%

UroGen Pharma EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$20.59 M(-30.5%)
-$97.82 M(+3.1%)
Jun 2024
-
-$29.64 M(+0.7%)
-$94.89 M(+11.5%)
Mar 2024
-
-$29.43 M(+62.2%)
-$85.13 M(+3.9%)
Dec 2023
-$81.90 M(-16.2%)
-$18.15 M(+2.8%)
-$81.90 M(-7.2%)
Sep 2023
-
-$17.66 M(-11.2%)
-$88.26 M(-4.7%)
Jun 2023
-
-$19.89 M(-24.1%)
-$92.59 M(-4.2%)
Mar 2023
-
-$26.20 M(+6.9%)
-$96.65 M(-1.2%)
Dec 2022
-$97.77 M(-9.1%)
-$24.51 M(+11.4%)
-$97.77 M(-2.4%)
Sep 2022
-
-$21.99 M(-8.1%)
-$100.13 M(-7.2%)
Jun 2022
-
-$23.94 M(-12.4%)
-$107.90 M(-1.4%)
Mar 2022
-
-$27.33 M(+1.7%)
-$109.42 M(+1.5%)
Dec 2021
-$107.60 M(-13.7%)
-$26.86 M(-9.7%)
-$107.78 M(+0.2%)
Sep 2021
-
-$29.76 M(+16.8%)
-$107.55 M(+1.1%)
Jun 2021
-
-$25.47 M(-0.8%)
-$106.42 M(-5.2%)
Mar 2021
-
-$25.69 M(-3.6%)
-$112.28 M(-10.0%)
Dec 2020
-$124.69 M
-$26.64 M(-6.9%)
-$124.69 M(-9.3%)
Sep 2020
-
-$28.63 M(-8.6%)
-$137.50 M(+4.2%)
DateAnnualQuarterlyTTM
Jun 2020
-
-$31.32 M(-17.8%)
-$132.01 M(+6.3%)
Mar 2020
-
-$38.10 M(-3.4%)
-$124.13 M(+14.8%)
Dec 2019
-$108.15 M(+40.9%)
-$39.44 M(+70.4%)
-$108.15 M(+16.7%)
Sep 2019
-
-$23.14 M(-1.3%)
-$92.66 M(+2.3%)
Jun 2019
-
-$23.45 M(+6.0%)
-$90.55 M(+5.9%)
Mar 2019
-
-$22.13 M(-7.6%)
-$85.49 M(+11.4%)
Dec 2018
-$76.76 M(+288.8%)
-$23.95 M(+13.9%)
-$76.76 M(+22.0%)
Sep 2018
-
-$21.03 M(+14.4%)
-$62.91 M(+49.2%)
Jun 2018
-
-$18.38 M(+37.2%)
-$42.17 M(+42.2%)
Mar 2018
-
-$13.40 M(+32.7%)
-$29.65 M(+50.2%)
Dec 2017
-$19.74 M(-2052.8%)
-$10.10 M(+3431.5%)
-$19.74 M(-555.0%)
Sep 2017
-
-$286.00 K(-95.1%)
$4.34 M(-403.9%)
Jun 2017
-
-$5.86 M(+67.9%)
-$1.43 M(-232.3%)
Mar 2017
-
-$3.49 M(-125.0%)
$1.08 M(-76.4%)
Dec 2016
$1.01 M(-108.2%)
$13.98 M(-331.0%)
$4.57 M(-148.6%)
Sep 2016
-
-$6.05 M(+80.3%)
-$9.41 M(+180.3%)
Jun 2016
-
-$3.36 M
-$3.36 M
Dec 2015
-$12.30 M
-
-

FAQ

  • What is UroGen Pharma annual EBITDA?
  • What is the all time high annual EBITDA for UroGen Pharma?
  • What is UroGen Pharma annual EBITDA year-on-year change?
  • What is UroGen Pharma quarterly EBITDA?
  • What is the all time high quarterly EBITDA for UroGen Pharma?
  • What is UroGen Pharma quarterly EBITDA year-on-year change?
  • What is UroGen Pharma TTM EBITDA?
  • What is the all time high TTM EBITDA for UroGen Pharma?
  • What is UroGen Pharma TTM EBITDA year-on-year change?

What is UroGen Pharma annual EBITDA?

The current annual EBITDA of URGN is -$81.90 M

What is the all time high annual EBITDA for UroGen Pharma?

UroGen Pharma all-time high annual EBITDA is $1.01 M

What is UroGen Pharma annual EBITDA year-on-year change?

Over the past year, URGN annual EBITDA has changed by +$15.87 M (+16.23%)

What is UroGen Pharma quarterly EBITDA?

The current quarterly EBITDA of URGN is -$20.59 M

What is the all time high quarterly EBITDA for UroGen Pharma?

UroGen Pharma all-time high quarterly EBITDA is $13.98 M

What is UroGen Pharma quarterly EBITDA year-on-year change?

Over the past year, URGN quarterly EBITDA has changed by -$2.94 M (-16.63%)

What is UroGen Pharma TTM EBITDA?

The current TTM EBITDA of URGN is -$97.82 M

What is the all time high TTM EBITDA for UroGen Pharma?

UroGen Pharma all-time high TTM EBITDA is $4.57 M

What is UroGen Pharma TTM EBITDA year-on-year change?

Over the past year, URGN TTM EBITDA has changed by -$9.56 M (-10.84%)